Dr. Reddy's Laboratories Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Dr. Reddy's Laboratories şirketinin toplam hissedar öz sermayesi ₹309.3B ve toplam borcu ₹43.8B olup, bu da borç-öz sermaye oranını 14.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹466.0B ve ₹156.7B dir. Dr. Reddy's Laboratories 'in FAVÖK'ü ₹67.7B faiz karşılama oranı -227.8 dur. Şirketin ₹63.1B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

14.2%

Borç/özkaynak oranı

₹43.82b

Borç

Faiz karşılama oranı	-227.8x
Nakit	₹63.07b
Eşitlik	₹309.28b
Toplam yükümlülükler	₹156.67b
Toplam varlıklar	₹465.96b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 500124 'nin kısa vadeli varlıkları ( ₹248.1B ) kısa vadeli yükümlülüklerini ( ₹129.3B ) aşıyor.

Uzun Vadeli Yükümlülükler: 500124 şirketinin kısa vadeli varlıkları ( ₹248.1B ) uzun vadeli yükümlülüklerini ( ₹27.4B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 500124 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 500124 'nin borç/öz sermaye oranı son 5 yılda 19.3% seviyesinden 14.2% seviyesine düştü.

Borç Kapsamı: 500124 'nin borcu işletme nakit akışı ( 77.7% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 500124 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Dr. Reddy's Laboratories Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Limited Complaint Made Public in the United States District Court for the District of New Jersey

Dr. Reddy's Laboratories Limited to Report Q2, 2025 Results on Nov 05, 2024

Dr. Reddy's and Nestle Health Science Appoints Mansi Khanna as Chief Operating Officer

Price target increased by 7.3% to ₹6,611

Dr. Reddy's Laboratories Limited Approves Dividend for the Fiscal Year 2024

Dr. Reddy's Receives Positive CHMP Opinion from European Medicines Agency for Its Proposed Rituximab Biosimilar

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited to Report Q1, 2025 Results on Jul 27, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Dr. Reddy's Laboratories Limited Announces Appointment of Milan Kalawadia as Chief Executive Officer, North America

Dividend of ₹40.00 announced

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Dr. Reddy's Laboratories Limited Announces Chief Financial Officer Changes

Dr. Reddy's Laboratories Limited Announces Executive Changes

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

Dr. Reddy's Laboratories Limited Announces Change in Management

Dr. Reddy's Laboratories Limited Announces Appointment of Sanjiv Mehta as Additional Director

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed GMP and Pre-Approval Inspection

Dr. Reddy's Laboratories Ltd. Announces the Roll-Out of Nerivio in India

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Dr. Reddy's Laboratories Ltd. Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S

Dr. Reddy's Laboratories Limited Announces Resignation of Mukesh Rathi as Chief Information Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2023

Price target increased by 7.7% to ₹5,388

Dr. Reddy's Laboratories Limited Announces Management Changes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Announces Its Proposed Rituximab Biosimilar Application Acceptance for Review by USFDA, EMA and MHRA

Upcoming dividend of ₹40.00 per share at 0.8% yield

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Completes Phase I Study (IV Route) of DRL_TC

Dr. Reddy's Laboratories Limited Reports Impairment Charges for the Fourth Quarter Ended March 31, 2023

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 27, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Announces the Launch of Regadenoson Injection 0.4 Mg/5 Ml in the U.S

Dr. Reddy's Laboratories Limited Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Completes Full Set of Clinical Studies of Its Rituximab Biosimilar for Filing in the U.S., Europe

Dr. Reddy’S Launches In-House Palbociclib (Primcyv®) to Widen Access to High-Quality Breast Cancer Drug

Dr. Reddy's Laboratories Limited Announces Resignation of Allan Grant Oberman as an Independent Director

Dr. Reddy's Laboratories Provides Updates on Litigation

Dr. Reddy's Laboratories Limited to Report Q3, 2023 Results on Jan 25, 2023

Dr. Reddy s Laboratories Ltd. Announces Tocilizumab Biosimilar Candidate, DRL_TC, Successfully Met Its Primary and Secondary Endpoints in A Phase 1 Study

Consensus EPS estimates increase by 17%

Dr. Reddy's Laboratories Limited Announces Change in Directorate

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Dr. Reddy's Laboratories Limited Appoints Mr. Arun Madhavan Kumar as an Independent Director

Dr. Reddy's Laboratories Limited to Report Q2, 2023 Results on Oct 28, 2022

Dr. Reddy's Laboratories Limited Informs Bruce L A Carter, Independent Director of the Company Has Ceased to Be A Director

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Dr. Reddy's Laboratories Limited Appoints Arun Madhavan Kumar as an Independent Additional Director

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 Mg Single-Dose Vial in the U.S. Market

Dr. Reddy's Laboratories Limited Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed Pre-Approval Inspection At Formulations Manufacturing Facility FTO 11 in Srikakulam, Andhra Pradesh

Upcoming dividend of ₹30.00 per share

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 98 million.

Dr. Reddy's Laboratories Limited to Report Q1, 2023 Results on Jul 28, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film

Dr. Reddy's Laboratories Announces the Launch of the Generic Version of Nexavar (Sorafenib) Tablets, USP, 200 Mg in the U.S. Market

Dr. Reddy’S Laboratories Ltd. Announces the Launch of Pemetrexed for Injection, 100 Mg and 500 Mg Single-Dose Vials, the Generic Equivalent of Alimta® (Pemetrexed for Injection) in the U.S. Market Approved by the U.S. Food and Drug Administration

Torrent Pharmaceuticals Limited (BSE:500420) entered into an agreement to acquire Styptovit-E, Finast, Finast-T and Dynapress brands from Dr. Reddy's Laboratories Limited (BSE:500124).